Improving the future of cancer care through clinical studies

We’re proud to partner with leading investigators at medical centers and biopharmaceutical companies to help transform how cancer is detected, treated, and managed.

Information on Guardant Health studies can be found on Medical professionals and clinical researchers may also email us to learn more about study participation.

Our cancer screening
clinical studies

Imagine a day when screening for cancer is as simple as performing a blood test. We are collaborating with thought leaders and their institutions around the world in pursuit of this future. We are starting first with colorectal cancer, which is the second leading cause of cancer death globally and a cancer where incidence is increasing in younger adults.


Cancer screening is a proven way to detect colorectal cancer early, when it can most effectively be treated. Current guidelines recommend that average-risk adults begin colorectal cancer screening starting at 45 years old. Yet an estimated 1 in 3 people in the U.S. are not getting screening1. Depending on the modality, screening can be invasive, difficult to complete, and time-consuming. We are developing our LUNAR-2 blood test to overcome these barriers and help increase cancer screening rates.

The ECLIPSE clinical trial is a large-scale colorectal cancer screening study to evaluate the performance of our LUNAR-2 blood test to detect early signs of colorectal cancer in average-risk adults. One of the largest cancer screening studies of its kind, the prospective, multi-site registrational study reached target enrollment of 12,750 patients between the ages of 45-84 from across the U.S. Subject to positive study results, this study will support a premarket approval (PMA) submission to the FDA.


Symptoms of lung cancer don’t appear until the disease is already at an advanced stage. That’s why it’s so important to find lung cancer early before symptoms start. Current guidelines recommend yearly lung cancer screening using a low-dose computer tomography (CT) scan for people aged 50 to 80 years old who are at high risk for lung cancer.2 Despite these recommendations, only 14% of people eligible for a low-dose CT scan are up to date with screening recommendations.3

We believe a simple blood test could help improve screening rates and detect lung cancer early, when it can most easily be treated.

The SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study is a large-scale registrational study to evaluate the performance of our LUNAR-2 blood test to detect lung cancer in high-risk individuals aged 50-80. The study plans to enroll nearly 10,000 patients and will be conducted across approximately 100 centers in the United States and Europe.